Pieris Pharmaceuticals, Inc.
Extract: Bylaws Amendment (Plain English Desc) from a 8-K on 09/03/2019   Download
SEC Document
SEC Filing
On August 30, 2019, the Board adopted amendments (the “Amendments”) to Sections 1 and 2 of Article IV of the Company's amended and restated bylaws (the “Amended and Restated Bylaws”) to remove the requirement that the Company maintain an officer with the title “Chief Financial Officer.”